Biallelic ATM inactivation significantly reduces survival in patients treated on the United Kingdom leukemia research fund chronic lymphocytic leukemia 4 trial

by Skowronska, A., Parker, A., Oldreive, C., Davis, Z., Richards, S., Dyer, M., Matutes, E., Gonzalez, D., Taylor, A.M, Moss, P., Thomas, P., Oscier, D.G, Stankovic, T.
Published 2012

ATM mutation rather than BIRC3 deletion and/or mutation predicts reduced survival in 11q-deleted chronic lymphocytic leukemia: data from the UK LRF CLL4 trial

by Rose-Zerilli, Matthew J., Forster, Jade, Parker, Helen, Parker, Anton, Rodríguez, Ana E., Chaplin, Tracy, Gardiner, Anne, Steele, Andrew J., Collins, A., Young, Bryan D., Skowronska, Anna, Catovsky, Daniel, Stankovic, Tanja, Oscier, D.G, Strefford, Jonathan C.
Published 2014

The clinical significance of NOTCH1 and SF3B1 mutations in the UK LRF CLL4 trial

by Oscier, D.G, Rose-Zerilli, M.J.J, Winkelmann, N., de Castro, D.G, Gomez, B., Forster, J., Parker, Helen, Parker, A., Gardiner, A., Collins, Andrew, Else, M., Cross, N.C.P, Catovsky, D., Strefford, J.C
Published 2013